DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for benign urinary system neoplasm — screening already-approved drugs against its 30-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign urinary system neoplasm maps to a 30-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign urinary system neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
complement C1q A chain (C1QA) — C1QA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2drdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2WNV · 1.25 Å · ligand 2-deoxy-beta-D-erythro-pentofuranose (2DR). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2003 · 35 citations · open access
Molecular pathogenesis of urothelial bladder cancer.
AbstractCarcinoma of the urinary bladder is the second most common urologic malignancy. In addition, these tumors are one of the best understood genitourinary neoplasms with a well defined etiology, natural history, tumor biology, treatment options and outcome. This level of understanding arises as a consequence of multiple factors and represents a convergence of knowledge from diverse scientific disciplines. Insight provided by these disciplines, coupled with unique features of this neoplasm which make it assessable for detection, monitoring and treatment, combine to make this disease a model system for modern oncology. The intent of this review is to provide the reader an overview of our current understanding of this tumor from the standpoint of its molecular biology as related to tumor development and progression.
Endoscopic laser resection of a ureteral tumour in primary multiple malignant neoplasms
AbstractA case of the ureteral tumour endoscopic treatment is presented in a patient with primary multiple malignancies. In the case of polyneoplasia, there are usually two or more neoplasms of different localizations, including the organs of the urinary system. The kidney and prostate tumours are diagnosed more often, but in rare cases, ureter neoplasms. It is especially important to perform organ-sparing surgeries when diagnosing ureter neoplasms. In addition, chronic kidney disease after radical nephroureterectomy can be a relative contraindication to further chemoradiation therapy in polyneoplasias. In this patient, along with the breast and vulva neoplasms, a solitary tumour of the right ureter's lower third was detected, which was successfully removed endoscopically. The chosen method of minimally invasive treatment allowed to preserve a normal functioning kidney, to avoid the development of chronic kidney disease in the patient, who was later scheduled for chemotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
